4D Pharma to Participate in Upcoming Cantor Fitzgerald Microbiome Leaders Panel
February 16 2021 - 6:00AM
Business Wire
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the
development of Live Biotherapeutic products (LBPs) - a novel class
of drug derived from the microbiome, today announces Duncan Peyton,
Chief Executive Officer of 4D pharma, will participate in Cantor
Fitzgerald’s virtual panel, titled “Microbiome Players with Guided
Readouts in 2021,” on Thursday, February 18, 2021 at 15:00 GMT
(10:00 ET).
A webcast of the panel will be available via the “Events”
section of the 4D pharma website at www.4dpharmaplc.com.
About 4D pharma
Founded in February 2014, 4D pharma is a world leader in the
development of Live Biotherapeutics, a novel and emerging class of
drugs, defined by the FDA as biological products that contain a
live organism, such as a bacterium, that is applicable to the
prevention, treatment or cure of a disease. 4D has developed a
proprietary platform, MicroRx®, that rationally identifies Live
Biotherapeutics based on a deep understanding of function and
mechanism.
4D pharma's Live Biotherapeutic products (LBPs) are orally
delivered single strains of bacteria that are naturally found in
the healthy human gut. The Company has six clinical programs,
namely a Phase I/II study of MRx0518 in combination with KEYTRUDA
(pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a
neoadjuvant setting for patients with solid tumors, a Phase I study
of MRx0518 in patients with pancreatic cancer, a Phase I/II study
of MRx-4DP0004 in asthma (NCT03851250), a Phase II study of
MRx-4DP0004 in patients hospitalized with COVID-19 (NCT04363372),
and Blautix® in Irritable Bowel Syndrome (IBS) (NCT03721107) which
has completed a successful Phase II trial. Preclinical-stage
programs include candidates for CNS disease such as Parkinson's
disease and other neurodegenerative conditions. The Company has a
research collaboration with MSD, a tradename of Merck & Co.,
Inc., Kenilworth, NJ, USA, to discover and develop Live
Biotherapeutics for vaccines.
For more information, refer to www.4dpharmaplc.com.
Forward-Looking Statements
This press release contains "forward-looking statements." All
statements other than statements of historical fact contained in
this announcement, including without limitation statements
regarding timing of the clinical trial are forward-looking
statements within the meaning of Section 27A of the United States
Securities Act of 1933, as amended (the "Securities Act"), and
Section 21E of the United States Securities Exchange Act of 1934,
as amended (the "Exchange Act"). Forward-looking statements are
often identified by the words "believe," "expect," "anticipate,"
"plan," "intend," "foresee," "should," "would," "could," "may,"
"estimate," "outlook" and similar expressions, including the
negative thereof. The absence of these words, however, does not
mean that the statements are not forward-looking. These
forward-looking statements are based on the Company's current
expectations, beliefs and assumptions concerning future
developments and business conditions and their potential effect on
the Company. While management believes that these forward-looking
statements are reasonable as and when made, there can be no
assurance that future developments affecting the Company will be
those that it anticipates.
All of the Company's forward-looking statements involve known
and unknown risks and uncertainties, some of which are significant
or beyond its control, and assumptions that could cause actual
results to differ materially from the Company's historical
experience and its present expectations or projections. The
foregoing factors and the other risks and uncertainties that affect
the Company's business, including the risks of delays in the
commencement of the clinical trial and those additional risks and
uncertainties described the documents filed by the Company with the
US Securities and Exchange Commission (“SEC”), should be carefully
considered. The Company wishes to caution you not to place undue
reliance on any forward-looking statements, which speak only as of
the date hereof. The Company undertakes no obligation to publicly
update or revise any of its forward-looking statements after the
date they are made, whether as a result of new information, future
events or otherwise, except to the extent required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210216005184/en/
4D pharma Duncan Peyton, Chief Executive Officer +44 (0)113 895
0130 Investor Relations: ir@4dpharmaplc.com
Investors: Julie Seidel, Stern Investor Relations, Inc.
+1-212-362-1200 Julie.seidel@sternir.com
N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20
7496 3000 Philip Davies / Iqra Amin / James Fischer (Corporate
Finance) Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20
7332 2500 Dominic Wilson / Phil Walker
Image Box Communications Neil Hunter / Michelle Boxall
+44 (0)20 8943 4685 neil@ibcomms.agency /
michelle@ibcomms.agency
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Mar 2024 to Apr 2024
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Apr 2023 to Apr 2024